Neurohumoral modulation during waon therapy in chronic heart failure: Subanalysis of Waon-CHF study

Tomoko Ichiki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Heart failure (HF) is a disease of neurohumoral dysfunction and current pharmacological therapies for HF have not improved mortality rates, thus requiring additional new strategies. Waon therapy for HF patients may be a complementary strategy with peripheral vasodilation via nitric oxide. We hypothesized that Waon therapy would improve neurohumoral factors, such as natriuretic peptides (NP) and the renin-angiotensin-aldosterone system (RAAS) in HF. Methods and Results: Plasma samples were collected from patients enrolled in the WAON-CHF Study (Waon therapy (n=77) or control (n=73)) before and after the treatment. B-type NP (BNP), C-type NP (CNP), and aldosterone (Aldo) levels were measured by respective specific radioimmunoassays. Although clinical parameters significantly improved in the Waon group compared with the control group, BNP, Aldo, and CNP levels were not statistically different between groups. On subanalysis with patient variables, BNP levels were improved in the Waon group treated with angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker or spironolactone. In addition, Aldo levels were improved in the Waon group patients with diabetes mellitus, hypertension, and inotrope use, and CNP levels were improved in Waon group patients with estimated glomerular filtration rate <60 mL/min/1.73 m2. These changes were not observed in the control group. Conclusions: Waon therapy may accelerate the favorable actions of RAAS modulators in HF. (WAON-CHF Study: UMIN000006705)

Original languageEnglish (US)
Pages (from-to)700-716
Number of pages17
JournalCirculation Journal
Volume81
Issue number5
DOIs
StatePublished - 2017

Fingerprint

Heart Failure
Aldosterone
Renin-Angiotensin System
Therapeutics
C-Type Natriuretic Peptide
Control Groups
Natriuretic Peptides
Spironolactone
Brain Natriuretic Peptide
Angiotensin Receptor Antagonists
Glomerular Filtration Rate
Angiotensin-Converting Enzyme Inhibitors
Vasodilation
Radioimmunoassay
Diabetes Mellitus
Nitric Oxide
Pharmacology
Hypertension
Mortality

Keywords

  • Heart failure
  • Natriuretic peptides
  • Renin-angiotensin-aldosterone system
  • Waon therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Neurohumoral modulation during waon therapy in chronic heart failure : Subanalysis of Waon-CHF study. / Ichiki, Tomoko.

In: Circulation Journal, Vol. 81, No. 5, 2017, p. 700-716.

Research output: Contribution to journalArticle

@article{2e509e0ad92343a7b6926e58b93f705a,
title = "Neurohumoral modulation during waon therapy in chronic heart failure: Subanalysis of Waon-CHF study",
abstract = "Background: Heart failure (HF) is a disease of neurohumoral dysfunction and current pharmacological therapies for HF have not improved mortality rates, thus requiring additional new strategies. Waon therapy for HF patients may be a complementary strategy with peripheral vasodilation via nitric oxide. We hypothesized that Waon therapy would improve neurohumoral factors, such as natriuretic peptides (NP) and the renin-angiotensin-aldosterone system (RAAS) in HF. Methods and Results: Plasma samples were collected from patients enrolled in the WAON-CHF Study (Waon therapy (n=77) or control (n=73)) before and after the treatment. B-type NP (BNP), C-type NP (CNP), and aldosterone (Aldo) levels were measured by respective specific radioimmunoassays. Although clinical parameters significantly improved in the Waon group compared with the control group, BNP, Aldo, and CNP levels were not statistically different between groups. On subanalysis with patient variables, BNP levels were improved in the Waon group treated with angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker or spironolactone. In addition, Aldo levels were improved in the Waon group patients with diabetes mellitus, hypertension, and inotrope use, and CNP levels were improved in Waon group patients with estimated glomerular filtration rate <60 mL/min/1.73 m2. These changes were not observed in the control group. Conclusions: Waon therapy may accelerate the favorable actions of RAAS modulators in HF. (WAON-CHF Study: UMIN000006705)",
keywords = "Heart failure, Natriuretic peptides, Renin-angiotensin-aldosterone system, Waon therapy",
author = "Tomoko Ichiki and Tomoko Ichiki and Burnett, {John C Jr.} and Scott, {Christopher G.} and Heublein, {Denise M.} and Masaaki Miyata and Koichiro Kinugawa and Teruo Inoue and Chuwa Tei and Tohru Masuyama and Hiroshi Inoue and Hirofumi Noike and Toshihiko Muramatsu and Yasuchika Takeishi and Keijiro Saku and Kazumasa Harada and Hiroyuki Daida and Youichi Kobayashi and Nobuhisa Hagiwara and Masatoshi Nagayama and Shinichi Momomura and Kazuya Yonezawa and Hiroshi Ito and Satoshi Gojo and Makoto Akaishi and Mitsuru Ohish and Ryozo Nagai and Shunei Kyo and Minoru Ono and Hitonobu Tomoike and Yasuo Oohashi and Shigeru Toyoda and Takuro Kubozono and Mitsuo Sobajima and Kanta Hujimi and Shinichi Hirotani and Takahiro Nakagami and Masamitsu Sugie and Itimon Nakamura and Miho Yokoyama and Akiomi Yoshihisa and Shinji Koba and Tsuyoshi Shiga and Megumi Shimada and Yuko Yamamoto and Ai Okazaki and Tomohito Suzuki and Nobutoshi Sugiyama",
year = "2017",
doi = "10.1253/circj.CJ-16-1117",
language = "English (US)",
volume = "81",
pages = "700--716",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "5",

}

TY - JOUR

T1 - Neurohumoral modulation during waon therapy in chronic heart failure

T2 - Subanalysis of Waon-CHF study

AU - Ichiki, Tomoko

AU - Ichiki, Tomoko

AU - Burnett, John C Jr.

AU - Scott, Christopher G.

AU - Heublein, Denise M.

AU - Miyata, Masaaki

AU - Kinugawa, Koichiro

AU - Inoue, Teruo

AU - Tei, Chuwa

AU - Masuyama, Tohru

AU - Inoue, Hiroshi

AU - Noike, Hirofumi

AU - Muramatsu, Toshihiko

AU - Takeishi, Yasuchika

AU - Saku, Keijiro

AU - Harada, Kazumasa

AU - Daida, Hiroyuki

AU - Kobayashi, Youichi

AU - Hagiwara, Nobuhisa

AU - Nagayama, Masatoshi

AU - Momomura, Shinichi

AU - Yonezawa, Kazuya

AU - Ito, Hiroshi

AU - Gojo, Satoshi

AU - Akaishi, Makoto

AU - Ohish, Mitsuru

AU - Nagai, Ryozo

AU - Kyo, Shunei

AU - Ono, Minoru

AU - Tomoike, Hitonobu

AU - Oohashi, Yasuo

AU - Toyoda, Shigeru

AU - Kubozono, Takuro

AU - Sobajima, Mitsuo

AU - Hujimi, Kanta

AU - Hirotani, Shinichi

AU - Nakagami, Takahiro

AU - Sugie, Masamitsu

AU - Nakamura, Itimon

AU - Yokoyama, Miho

AU - Yoshihisa, Akiomi

AU - Koba, Shinji

AU - Shiga, Tsuyoshi

AU - Shimada, Megumi

AU - Yamamoto, Yuko

AU - Okazaki, Ai

AU - Suzuki, Tomohito

AU - Sugiyama, Nobutoshi

PY - 2017

Y1 - 2017

N2 - Background: Heart failure (HF) is a disease of neurohumoral dysfunction and current pharmacological therapies for HF have not improved mortality rates, thus requiring additional new strategies. Waon therapy for HF patients may be a complementary strategy with peripheral vasodilation via nitric oxide. We hypothesized that Waon therapy would improve neurohumoral factors, such as natriuretic peptides (NP) and the renin-angiotensin-aldosterone system (RAAS) in HF. Methods and Results: Plasma samples were collected from patients enrolled in the WAON-CHF Study (Waon therapy (n=77) or control (n=73)) before and after the treatment. B-type NP (BNP), C-type NP (CNP), and aldosterone (Aldo) levels were measured by respective specific radioimmunoassays. Although clinical parameters significantly improved in the Waon group compared with the control group, BNP, Aldo, and CNP levels were not statistically different between groups. On subanalysis with patient variables, BNP levels were improved in the Waon group treated with angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker or spironolactone. In addition, Aldo levels were improved in the Waon group patients with diabetes mellitus, hypertension, and inotrope use, and CNP levels were improved in Waon group patients with estimated glomerular filtration rate <60 mL/min/1.73 m2. These changes were not observed in the control group. Conclusions: Waon therapy may accelerate the favorable actions of RAAS modulators in HF. (WAON-CHF Study: UMIN000006705)

AB - Background: Heart failure (HF) is a disease of neurohumoral dysfunction and current pharmacological therapies for HF have not improved mortality rates, thus requiring additional new strategies. Waon therapy for HF patients may be a complementary strategy with peripheral vasodilation via nitric oxide. We hypothesized that Waon therapy would improve neurohumoral factors, such as natriuretic peptides (NP) and the renin-angiotensin-aldosterone system (RAAS) in HF. Methods and Results: Plasma samples were collected from patients enrolled in the WAON-CHF Study (Waon therapy (n=77) or control (n=73)) before and after the treatment. B-type NP (BNP), C-type NP (CNP), and aldosterone (Aldo) levels were measured by respective specific radioimmunoassays. Although clinical parameters significantly improved in the Waon group compared with the control group, BNP, Aldo, and CNP levels were not statistically different between groups. On subanalysis with patient variables, BNP levels were improved in the Waon group treated with angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker or spironolactone. In addition, Aldo levels were improved in the Waon group patients with diabetes mellitus, hypertension, and inotrope use, and CNP levels were improved in Waon group patients with estimated glomerular filtration rate <60 mL/min/1.73 m2. These changes were not observed in the control group. Conclusions: Waon therapy may accelerate the favorable actions of RAAS modulators in HF. (WAON-CHF Study: UMIN000006705)

KW - Heart failure

KW - Natriuretic peptides

KW - Renin-angiotensin-aldosterone system

KW - Waon therapy

UR - http://www.scopus.com/inward/record.url?scp=85018669889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018669889&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-16-1117

DO - 10.1253/circj.CJ-16-1117

M3 - Article

C2 - 28202884

AN - SCOPUS:85018669889

VL - 81

SP - 700

EP - 716

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 5

ER -